How will Kent MenB vaccine eligibility change?

Experts review whether MenB vaccines should reach more people

After the meningitis B (MenB) outbreak in Kent, a scientific advisory committee is considering whether to expand vaccine eligibility. The key issue is coverage: the MenB strain involved in the outbreak is one that many people are not routinely vaccinated against, and public health action has already focused on quickly protecting students and close contacts.

The expanded review comes as authorities weigh the balance between urgency and evidence. During the outbreak, vaccination campaigns were used alongside other measures such as antibiotics for people deemed at risk, and there was a notable increase in access attempts—pharmacies reported rising demand for meningitis jabs and UK health leaders used targeted vaccination for university accommodation populations.

What the potential change would mean in practice is broader access to MenB vaccination beyond the current group for whom it is standard. The advisory discussion focuses on whether additional eligibility would reduce the chance of further spread in similar community settings.

The significance for public health is twofold:

• Faster risk reduction: If more groups are eligible, authorities can vaccinate proactively rather than only after a surge begins.
• Better preparedness: An outbreak that spreads unusually quickly can expose gaps in existing immunization strategy.

Even as experts evaluate eligibility, the outbreak has underscored the importance of rapid recognition and treatment of symptoms because meningococcal disease can progress quickly.

It remains to be seen what the committee will recommend. The stories describe an active process to examine how offering routine MenB jabs to a wider range of people could affect outbreak control and future prevention, rather than announcing a final policy change.